share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

諾和諾德 | 6-K：諾和諾德-股票回購計劃
美股sec公告 ·  05/28 18:07
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
全球領先的醫療保健公司諾和諾德A/S宣佈了其股票回購計劃的進展。該計劃於2024年5月6日啓動，是更大的12個月回購計劃的一部分，該計劃於2024年2月6日開始，總預算高達200億丹麥克朗。截至2024年5月27日，諾和諾德已根據當前計劃回購了436,152億股股票，總額爲397,178,886丹麥克朗。這些交易是在2024年5月17日至5月24日之間進行的，收購價格從每B股906.86丹麥克朗到937.21丹麥克朗不等。總體而言，自2月份回購計劃啓動以來，該公司已收購了9,170,402億股股票，平均價格爲864.18丹麥克朗，總額爲7,924,913,659丹麥克朗。這些回購的股份是公司庫存股的一部分，目前共有10,535,966股B股，佔股本的0.2％。諾和諾德成立於1923年，總部位於丹麥，致力於抗擊嚴重的慢性病，業務遍及80個國家，其產品銷往約170個國家。
全球領先的醫療保健公司諾和諾德A/S宣佈了其股票回購計劃的進展。該計劃於2024年5月6日啓動，是更大的12個月回購計劃的一部分，該計劃於2024年2月6日開始，總預算高達200億丹麥克朗。截至2024年5月27日，諾和諾德已根據當前計劃回購了436,152億股股票，總額爲397,178,886丹麥克朗。這些交易是在2024年5月17日至5月24日之間進行的，收購價格從每B股906.86丹麥克朗到937.21丹麥克朗不等。總體而言，自2月份回購計劃啓動以來，該公司已收購了9,170,402億股股票，平均價格爲864.18丹麥克朗，總額爲7,924,913,659丹麥克朗。這些回購的股份是公司庫存股的一部分，目前共有10,535,966股B股，佔股本的0.2％。諾和諾德成立於1923年，總部位於丹麥，致力於抗擊嚴重的慢性病，業務遍及80個國家，其產品銷往約170個國家。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。